EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

CANNABIDIOL AS AN EMERGING THERAPY FOR INFLAMMATORY CONTROL IN CANINE ATOPIC DERMATITIS: A NARRATIVE REVIEW

Adjanna Karla Leite Araújo, Rivaldo Vila Nova de Miranda, Terezinha Carla Carvalho da Silva, Valdemiro Amaro da Silva Júnior

Revista DCS · 18.05.2026 · 23 (90) · e5348

DOI: 10.54899/dcs.v23i90.5348 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Revista DCS, online erschienen am 18.05.2026. Verfasst von Adjanna Karla Leite Araújo und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Canine atopic dermatitis (CAD) is a chronic inflammatory skin disorder characterized by intense pruritus, epidermal barrier dysfunction, and an exacerbated immune response. Although conventional therapies—such as corticosteroids, cyclosporine, and Janus kinase inhibitors—are effective, long-term use is associated with adverse effects. Cannabidiol (CBD), a non-psychoactive compound derived from Cannabis sativa, has emerged as a promising topical therapeutic alternative due to its anti-inflammatory, antipruritic, and skin barrier-restorative properties. This narrative literature review was conducted through the analysis of scientific articles retrieved from databases and platforms such as PubMed, PMC, Google Scholar, ScienceDirect, and Wiley Online Library. Seventeen articles published between 2002 and 2024, in English and Portuguese, addressing the role of CBD in CAD management were included. The findings reveal that CBD modulates the cutaneous endocannabinoid system, downregulates pro-inflammatory cytokine production, alleviates pruritus, promotes epidermal barrier regeneration, and improves clinical signs. Preliminary studies in dogs demonstrated clinical efficacy with a low incidence of adverse effects and minimal systemic absorption. However, data on standardized formulations, species-specific pharmacokinetics, and randomized clinical trials remain limited. Topical CBD appears to be a promising adjunctive therapy for CAD, but further studies are warranted to confirm its safety, efficacy, and standardization in veterinary dermatology.

Zitieren

APA

Araújo, A. K. L., Miranda, R. V. N. D., Silva, T. C. C. D., & Júnior, V. A. D. S. (2026). CANNABIDIOL AS AN EMERGING THERAPY FOR INFLAMMATORY CONTROL IN CANINE ATOPIC DERMATITIS: A NARRATIVE REVIEW. Revista DCS, 23(90), e5348. https://doi.org/10.54899/dcs.v23i90.5348

Vancouver

Araújo AKL, Miranda RVND, Silva TCCD, Júnior VADS. CANNABIDIOL AS AN EMERGING THERAPY FOR INFLAMMATORY CONTROL IN CANINE ATOPIC DERMATITIS: A NARRATIVE REVIEW. Revista DCS. 2026;23(90):e5348. doi:10.54899/dcs.v23i90.5348

BibTeX
@article{Arajo2026,
  author = {Araújo, Adjanna Karla Leite and Miranda, Rivaldo Vila Nova de and Silva, Terezinha Carla Carvalho da and Júnior, Valdemiro Amaro da Silva},
  title = {CANNABIDIOL AS AN EMERGING THERAPY FOR INFLAMMATORY CONTROL IN CANINE ATOPIC DERMATITIS: A NARRATIVE REVIEW},
  journal = {Revista DCS},
  year = {2026},
  volume = {23},
  number = {90},
  pages = {e5348},
  doi = {10.54899/dcs.v23i90.5348}
}
Kostenlos starten →